CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM032146
Első szerző:Daragó Andrea (orvos, kardiológus)
Cím:Differences in Angiotensin Convertase Enzyme (ACE) Activity and Expression May Contribute to Shorter Event Free Period After Coronary Artery Bypass Graft Surgery / Daragó Andrea, Fagyas Miklós, Siket M. Ivetta, Facskó Andrea, Megyesi Zita, Kalász Judit, Galajda Zoltán, Szerafin Tamás, Hársfalvi Jolán, Édes István, Papp Zoltán, Tóth Attila, Szentmiklósi József
Dátum:2012
ISSN:1755-5914
Megjegyzések:Aims: The goal of this study was to investigate the importance of the vascular angiotensin convertase enzyme (ACE) in coronary artery bypass graft surgery (CABG) patients. Methods: Vascular tissue (distal saphenous vein [n= 163] and/or radial artery [n= 120] segments) and blood samples were collected from CABG patients (n= 81). We studied (i) the potency of angiotensin I (AngI) and angiotensin II (AngII) to evoke vascular contractions; (ii) vascular and plasma ACE concentrations; and (iii) ACE genotype of the patients enrolled. Results: The ratio of the potencies (EC(50) ) of AngII and AngI was significantly lower in radial artery compared to the saphenous vein (0.17 ? 0.03 nM and 0.51 ? 0.14 nM, respectively, P= 0.003), suggesting a 3-fold more effective AngI conversion in saphenous vein samples. Angiotensin constrictions were inhibited with telmisartan and captopril in both saphenous veins and radial arteries. Vascular ACE expression was significantly higher in saphenous vein compared to radial artery (9.7 ? 1.0 ng/mg and 5.3 ? 0.7 ng/mg, respectively, P= 0.01). Serum but no tissue ACE concentration was determined by ACE insertion/deletion polymorphism. Accordingly, no relation was found between serum and tissue ACE expression. Conclusion: ACE-inhibitor therapy targeting tissue located ACE may be beneficial to patients with saphenous vein grafts after CABG surgery.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Cardiovascular Therapeutics. - 30 : 3 (2012), p. 136-144. -
További szerzők:Fagyas Miklós (1984-) (orvos) Mányiné Siket Ivetta (1962-) (laborasszisztens) Facskó Andrea (1953-) (szemész) Megyesi Zita Kalász Judit (1986-) (molekuláris biológus) Galajda Zoltán (1962-) (szívsebész, érsebész) Szerafin Tamás (1960-) (szívsebész, mellkassebész) Hársfalvi Jolán (1949-) (klinikai biokémikus) Édes István (1952-) (kardiológus) Papp Zoltán (1965-) (kardiológus, élettanász) Tóth Attila (1971-) (biológus) Szentmiklósi József András (1948-) (farmakológus, klinikai laboratóriumi szakorvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM015747
Első szerző:Dhalla, Naranjan S.
Cím:Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure / Naranjan S. Dhalla, Melissa R. Dent, Paramjit S. Tappia, Rajat Sethi, Barta Judit, Ramesh K. Goyal
Dátum:2006
Megjegyzések:It is now well known that congestive heart failure (CHF) is invariably associated with cardiac hypertrophy, and changes in the shape and size of cardiomyocytes (cardiac remodeling) are considered to explain cardiac dysfunction in CHF. However, the mechanisms responsible for the transition of cardiac hypertrophy to heart failure are poorly understood. Several lines of evidence both from various experimental models of CHF and from patients with different types of CHF have indicated that the functions of different subcellular organelles such as extracellular matrix, sarcolemma, sarcoplasmic reticulum, myofibrils, mitochondria, and nucleus are defective. Subcellular abnormalities for protein contents, gene expression, andenzyme activities in the failing heart become evident as a consequence of prolonged hormonal imbalance, metabolic derangements, and cation maldistribution. In particular, the occurrence of oxidative stress, development of intracellular Ca2+ overload, activation of proteasesand phospholipases, and alterations in cardiac gene expression result in changes in the biochemical composition, molecular structure, and function of different subcellular organelles (subcellular remodeling). Not only does subcellular remodeling appear to be intimately involved in the transition of cardiac hypertrophy to heart failure, the mismatching of the function of different subcellular organelles leads to the development of cardiac dysfunction. Although blockade of the renin-angiotensin system, sympathetic nervous system, and various other hormonal actions have been reported to produce beneficial effects on cardiac remodeling and heart dysfunction in CHF, the actions of various cardiac drugs on subcellular remodeling have not been examined extensively. Some recent studies have indicated thatboth the angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists attenuate changes in sarcolemma, sarcoplasmic reticulum, and myofibril enzyme activities, protein contents, and gene expression, and partly improve cardiac function in the failing hearts. It is suggested that subcellular remodeling is an excellent target for the development of improved drug therapy for CHF. Furthermore, extensive studies should investigate theeffects of different agents individually or in combination on reverse subcellular remodeling, cardiac remodeling, and cardiac dysfunction in various experimental models of CHF.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
congestive heart failure
cardiac remodeling
subcellular remodeling
cardiac drugs
cardiac hypertrophy
cardiac dysfunction
Megjelenés:Journal of Cardiovascular Pharmacology and Therapeutics. - 11 : 1 (2006), p. 31-45. -
További szerzők:Dent, Melissa R. Tappia, Paramjit S. Sethi, Rajat Barta Judit (1975-) (kardiológus) Goyal, Ramesh K.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM040599
Első szerző:Nieminen, Markku S.
Cím:Effects of Levosimendan on the Energy Balance : Preclinical and Clinical Evidence / Markku S. Nieminen, Piero Pollesello, Gusztáv Vajda, Zoltán Papp
Dátum:2009
Megjegyzések:Levosimendan is a novel inodilator agent, which enhances myocardial performance without substantial changes in oxygen consumption. The combination of positive inotropic and vasodilator effects of levosimendan relates to its Ca-sensitizing and K channel opening effects. Levosimendan is one of the best documented pharmacological agents used in the management of acute heart failure syndromes. Interest in levosimendan has recently been renewed owing to its potential in supporting cardiac function in patients with ischemic heart disease and cardiogenic or septic shock. It has been also demonstrated that levosimendan can be used as a bridge therapy for the perioperative phase of cardiac surgery. The ability of levosimendan to improve myocardial function without substantially increasing oxygen consumption may appear paradoxical but is indeed possible via improved efficacy, not only with regard to the effects on the contractile apparatus of the cardiomyocytes but also when its composite hemodynamic effects are considered. The energy balance equation, therefore, should take into account the effect of levosimendan on all energy-consuming and energy-producing paths. Moreover, levosimendan-evoked KATP channel opening may possess favorable effects on mitochondrial adenosine triphosphate synthesis conferring cardioprotection during ischemic insults.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Cardiovascular Pharmacology and Therapeutics. - 53 : 4 (2009), p. 302-310. -
További szerzők:Pollesello, Piero Vajda Gusztáv (1956-) (kardiológus) Papp Zoltán (1965-) (kardiológus, élettanász)
Pályázati támogatás:K 68363
OTKA
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:
Rekordok letöltése1